In 2022, the Japanese Ministry of Health, Labor, and Welfare revised medical service fees, covering genetic testing for mitochondrial diseases under medical insurance plans. The Center for Diagnosis ...

SYDNEY, March 21, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (KZIA), a biotechnology company specialising in oncology, is pleased to announce that it has entered into an exclusive licensing ...

The gene ECHS1 encodes for enoyl-CoA hydratase short-chain 1, a mitochondrial enzyme involved in branched-chain amino acid and fatty acid metabolism. Rare inherited mutations in the ECHS1 lead to ...

Intestinal Stem Cells (ISCs) derived from a patient's own cells have garnered significant attention as a new alternative for ...

Researchers in Tokyo have broken ground in a gene therapy delivery method for diseases of the brain and central nervous system, and regenerative medicine for the intestinal tract. For more than a ...

Curamys to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to help advance its cell fusion technology. ROCKVILLE, Md. and SEOUL, South Korea, Dec. 04, 2022 (GLOBE NEWSWIRE) -- ...

Clonell Therapeutics, Inc., a leading biotechnology company dedicated to curing intractable and incurable diseases, announced today the official launch of the world's first 'Patient-Specific Embryonic ...

CAMBRIDGE, England--(BUSINESS WIRE)--Adrestia Therapeutics, a leader in synthetic rescue therapies for genetic diseases, today announced the appointment of Dr James Osborne as Head of Chemistry and ...

The incidence of inflammatory bowel disease (IBD) - an intractable disease characterized by chronic inflammation of the gastrointestinal (GI) tract - has increased significantly in Japan. Chronic ...